Notes: Sept. 22, 2023 -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors (“Board”) has approved a reverse stock split of the Company’s outstanding shares of common stock at a ratio of 1-for-5. The reverse stock split will become effective at 12:01 a.m. Eastern time on September 25, 2023. Neoleukin’s common stock will begin trading on a post-reverse stock split basis on September 25, 2023, under Neoleukin’s existing trading symbol “NLTX” with a new CUSIP number 64049K203. <p> Aug. 09, 2019 -- Neoleukin Therapeutics, Inc. (“Neoleukin”), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the completion of the previously disclosed merger transaction with Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP). Aquinox Pharmaceuticals, Inc. will be renamed Neoleukin Therapeutics, Inc. and will trade under the new ticker symbol “NLTX” beginning on Monday, August 12, 2019, on the Nasdaq Global Market.